Skip to content

Colfosceril Palmitate

    Brands

    DEA Class;  Rx

    Common Brand Names; EXOSURF NEONATAL

    • Respiratory stimulants and pulmonary surfactants
    Colfosceril Palmitate is a lung surfactant used for the prevention and treatment of respiratory distress syndrome in newborn babies with a birth weight of 700 grams or greater, undergoing mechanical ventilation. Close monitoring of heart rate and arterial oxygenation is recommended during treatment with this medicine.

    Colfosceril Palmitate is primarily indicated in conditions like Respiratory distress syndrome.

    Neonatal Respiratory Distress Syndrome

    Colfosceril Palmitate is contraindicated in conditions like Hypersensitivity to any component of product.

    The symptomatic adverse reactions produced by Colfosceril Palmitate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Pulmonary hemorrhage, Obstruction of the endotracheal tube by mucous secretions.

    Bleeding from lungs

    Irregular heart rate

    Birth weight

    Care must be taken for use in newborn babies whose birth weight is less than 700 gms due to an increase in the risk of pulmonary hemorrhage (bleeding from lungs) and other severe adverse effects. Close monitoring of heart rate and arterial oxygenation is recommended during treatment with this medicine.

    Intratracheal administration

    The medicine should be administered through intratracheal route only.

    Mucous plugging

    In newborns whose ventilation becomes notably impaired during or immediately after the therapy with this medicine may have mucus plugging of the endotracheal tube. Therefore, it is recommended to perform suctioning of all newborns to avoid endotracheal tube obstruction due to mucous plugging.

    Pregnancy

    This medicine is not recommended for use in pregnant women.

    Breast-feeding

    This medicine is not recommended for use in breastfeeding women.

    Adult

    5 ml/kg, 5 (5), As recommended., IV, Prophylactic treatment: 1st dose should be given after birth and 2nd and 3rd dose is given 12 and 24 hours later to infants

    Pediatrics

    No data regarding the Paedriatic dosage details of Colfosceril Palmitate is available

    Colfosceril Palmitate

    Injections